Table 2 Summary of evidence demonstrating direct effects of BCL3 on cancer therapeutic resistance
From: Multifaceted roles for BCL3 in cancer: a proto-oncogene comes of age
Cancer Type | Therapy intervention | Bcl3 expression | Ref |
|---|---|---|---|
CRC cells | DNA damage eg. (Radiotherapy) | ↓ Bcl3 expression sensitises to DNA damage | Parker C 2022 [116] |
Prostate cancer cells | Staurosporine Etoposide Paclitaxel | ↓ Bcl3 expression sensitised apoptosis and cell death | Ahlqvist 2013 [85] |
Prostate cancer cells | IL-6 | ↑ Bcl3 expression protected cells against apoptosis | Ahlqvist 2013 [85] |
Glioma | Temozolomide | ↑ expression of DcR1 decoy receptor via Bcl3 attenuates TMZ mediated apoptosis | Mansour 2015 [121] |
Glioma | Temozolomide | ↑ CAII expression via Bcl3 attenuates TMZ mediated apoptosis | Wu 201 8[92] |
Gastric Carcinoma cells | Oxoplatin 5-FU Irinotecan | Hypoxia ↑ Bcl3 expression ↓ Bcl3 expression induced sensitivity to chemotherapeutics | Hu 2020 [113] |
Breast Cancer cell line | Paclitaxel | ↓ Bcl3 expression increased resistance to Paclitaxel | Huo 2018 [40] |